Akari Therapeutics PLC (AKTX)
1.38
+0.04
(+2.99%)
USD |
NASDAQ |
May 07, 16:00
1.38
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics SG&A Expense (Quarterly)
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2022 | 2.965M |
| March 31, 2022 | 3.104M |
| December 31, 2021 | 2.021M |
| September 30, 2021 | 1.894M |
| June 30, 2021 | 2.147M |
| March 31, 2021 | 2.019M |
| December 31, 2020 | 2.235M |
| September 30, 2020 | 1.839M |
| June 30, 2020 | 2.891M |
| March 31, 2020 | 2.195M |
| December 31, 2019 | 2.125M |
| September 30, 2019 | 1.354M |
| June 30, 2019 | 2.438M |
| March 31, 2019 | 2.306M |
| December 31, 2018 | 3.153M |
| September 30, 2018 | 2.382M |
| June 30, 2018 | 2.858M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.297M |
| December 31, 2017 | 3.793M |
| September 30, 2017 | 2.159M |
| June 30, 2017 | 3.567M |
| March 31, 2017 | 2.280M |
| December 31, 2016 | 3.284M |
| September 30, 2016 | 2.228M |
| June 30, 2016 | 2.077M |
| March 31, 2016 | 2.352M |
| December 31, 2015 | 2.361M |
| September 30, 2015 | 2.730M |
| June 30, 2015 | 0.3108M |
| March 31, 2015 | 0.0997M |
| December 31, 2014 | 0.0289M |
| September 30, 2014 | 0.0555M |
| June 30, 2014 | 0.79M |
| March 31, 2014 | 1.083M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.354M
Minimum
Sep 2019
3.104M
Maximum
Mar 2022
2.248M
Average
2.147M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
| DBV Technologies SA | 6.443M |
| Cellectis SA | 4.671M |
| Adaptimmune Therapeutics PLC | 16.88M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 1.597M |